Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.

@article{Beksac2011AdditionOT,
  title={Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.},
  author={Meral Beksac and Rauf Haznedar and Tulin Firatli-Tuglular and Hakan Ozdoğu and Ismet Aydoğdu and Nahide Konuk and Gulsan A Sucak and Işık Kaygusuz and Sema Sadin Karakuş and E. E. Kaya and Rıdvan Ali and Zafer Gulbaş and Gulsum Ozet and Hakan Goker and Levent Undar},
  journal={European journal of haematology},
  year={2011},
  volume={86 1},
  pages={16-22}
}
The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules. This prospective trial differs from previous melphalan-prednisone (MP) vs. MPT trials by treatment dosing, duration, routine anticoagulation, and permission for a crossover. Newly diagnosed patients with multiple myeloma (MM) (n=122) aged greater than 55 yr, not eligible for transplantation were… CONTINUE READING